GR 99060

Drug Profile

GR 99060

Latest Information Update: 07 Feb 1996

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antifungals; Indoles; Small molecules; Triazines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 07 Feb 1996 A preclinical study has been added to the Mycoses pharmacodynamics and antimicrobial activity sections, and the pharmacokinetics section
  • 07 Feb 1996 Discontinued-Preclinical for Mycoses in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top